Top-News
Gesundheitswesen: Ausstattung u. Produkte USA

Seelos Therapeutics Inc News

Aktie
WKN:  A40DKU ISIN:  US81577F3073 US-Symbol:  SEEL
0,5720 €
+0,0183 €
+3,30%
0,6198 $ 24.06.24
Handeln Depot/Watchlist
Aktienanzahl *
622,92 Tsd.
Marktkapitalisierung *
325,52 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 16.05.2024

Seelos Therapeutics Inc News

16.05.24 - PR Newswire
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
14.05.24 - PR Newswire
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split PR Newswire
29.04.24 - PR Newswire
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations PR ...
19.03.24 - PR Newswire
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) PR Newswire
26.01.24 - PR Newswire
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-​the-Market Under Nasdaq Rules PR Newswire
22.01.24 - PR Newswire
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the ...
02.01.24 - PR Newswire
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 PR Newswire
22.12.23 - PR Newswire
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
Seelos Therapeutics, Inc. Releases Letter to its Stockholders PR Newswire
01.12.23 - PR Newswire
Seelos Therapeutics Announces Closing of Public Offering
Seelos Therapeutics Announces Closing of Public Offering PR Newswire
01.12.23 - PR Newswire
Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?
Thinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc? PR Newswire
29.11.23 - PR Newswire
Thinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?
Thinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness? PR Newswire
28.11.23 - PR Newswire
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering PR Newswire
28.11.23 - PR Newswire
Seelos Therapeutics Announces Proposed Public Offering
Seelos Therapeutics Announces Proposed Public Offering PR Newswire
27.11.23 - PR Newswire
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate ...
24.11.23 - PR Newswire
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split PR Newswire
27.10.23 - PR Newswire
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 PR Newswire
17.10.23 - PR Newswire
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations PR Newswire
28.09.23 - PR Newswire
Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll?
Thinking about buying stock in Oncolytics Biotech, Near Intelligence, Basin Uranium, Seelos Therapeutics, or MillerKnoll? PR Newswire
28.09.23 - PR Newswire
Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics?
Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics? PR Newswire
27.09.23 - PR Newswire
Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant?
Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant? PR Newswire

Newssuche

Videos

newspaper
03.07.24 +3,08%
Technical Trading: Bund Future Long Chance
Bund Future Long Typ: Turbo Open End WKN: VM3CG4 Hebel: 7,32 Laufzeit: OpenEnd Einstieg: Market ... Mehr »